CMS Part D Proposal Is “Solution In Search Of A Problem” – PhRMA’s Castellani
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA CEO John Castellani explains in an interview why Medicare Part D stakeholders are united in the concern that the sweeping changes proposed by CMS will “harm patients, limit choice and ultimately will raise costs in a program that by any measure is working well.”
You may also be interested in...
Mental Health Drugs Face Contracting Challenges From Part D Formulary Proposal
CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.